JP2009517405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517405A5 JP2009517405A5 JP2008542537A JP2008542537A JP2009517405A5 JP 2009517405 A5 JP2009517405 A5 JP 2009517405A5 JP 2008542537 A JP2008542537 A JP 2008542537A JP 2008542537 A JP2008542537 A JP 2008542537A JP 2009517405 A5 JP2009517405 A5 JP 2009517405A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- human
- binds
- protein
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 27
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 27
- 210000004408 Hybridomas Anatomy 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 5
- 102000038129 antigens Human genes 0.000 claims description 5
- 108091007172 antigens Proteins 0.000 claims description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims description 5
- 229960000060 monoclonal antibodies Drugs 0.000 claims description 5
- 230000001809 detectable Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 206010018651 Graft versus host disease Diseases 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 2
- 230000000890 antigenic Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000005962 mycosis fungoide Diseases 0.000 claims 2
- 230000004952 protein activity Effects 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010013554 Diverticulum Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 238000004166 bioassay Methods 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 101710027538 Aper1 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 108091006004 Fc-tagged proteins Proteins 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
Description
他の局面において、モノクローナル抗体は、モノクローナル抗体272.21.1.3.4.2(ATCCアクセッション番号PTA-10395)が結合するエピトープに特異的に結合する。他の態様において、モノクローナル抗体は、モノクローナル抗体268.5.1.11.42.1.4.3.9(ATCCアクセッション番号PTA-10394)が結合するエピトープに特異的に結合する。本発明のモノクローナル抗体はまた、検出可能なマーカーで標識してもよく、かつ、検出可能なマーカーは、放射性同位元素、酵素、色素、およびビオチンより選択することができるが、それらに限定されるわけではない。
別の局面において、本発明は、ヒトIL-21抗原に結合する際にモノクローナル抗体272.21.1.3.4.2(ATCCアクセッション番号PTA-10395)と競合することができるビン(bin)(または抗体のグループ)を提供する。
本発明の別の局面は、ヒトIL-21抗原に結合する際にモノクローナル抗体268.5.1.11.42.1.4.3.9(ATCCアクセッション番号PTA-10394)と競合することができるビンを提供する。
試料をハイブリドーマプールから採取し、かつ、中和アッセイ法および直接滴定ELISAの両方を用いて分析した。このアッセイ法では、どのクローンが最も高いOD測定値を維持し得るかを調べるために、4倍段階希釈物を用いて、試料を滴定した。中和アッセイ法および滴定アッセイ法の両方の結果を用いて、最初の大元の各ウェルから特定のクローンを、先に進めるために選択した。もう1度中和スクリーニングを実施して、これらの試料すべてを同じアッセイ法で試験し、かつ、この時点で、細胞株の数を上位4つの精選物に絞りこんだ。これらをさらにもう1回のクローニングに供して、培養物の均質性を徹底し、かつ、直接ELISAによってスクリーニングした。もう1回、滴定アッセイ法を実施した後、2種の最終IL-21クローンを選択し、268.5.1.11.42.1.4.3.9(ラット抗マウスIL-21、ATCCアクセッション番号PTA-10394)および272.21.1.3.4.2(ラット抗ヒトIL-21、ATCCアクセッション番号PTA-10395)と呼んだ。これらのハイブリドーマクローンによって産生されるモノクローナル抗体は、2mM L-グルタミン、100μg/mLペニシリン、および100μg/mL硫酸ストレプトマイシン、および10％ Fetal Clone I Serum(Hyclone Laboratories)を含む90％イスコフ改変ダルベッコ培地からなる増殖培地で培養することができる。これらのクローンは、2×105細胞/mlで培養を開始し、かつ、37℃、5％〜6％CO、1×105細胞/ml〜5×105細胞/mlの間で維持することによって、増殖させることができる。その後の移動の際に、細胞を無血清条件に順応させることができる。凍結した細胞を、90％血清、10％DMSO中で保存し、かつ、液体窒素冷凍器の気相中で保存する。
（表３）
ラット抗体272.21.1.3.4.2
C末端に結合されたペプチド1および結合されていないペプチド1の両方と少し反応する能力、hIL-21を中和できるが、溶液からhIL-21-Fcを捕捉できないことに基づき、この抗体は、IL-21のN末端およびAヘリックスの領域中に存在し、かつ、Fc融合タンパク質に連結されているhIL-21の隣接したC末端の近くに空間を必要とすると予測される部分を含む、ヒトIL-21タンパク質構造体上のかなり不連続なエピトープに結合する。
C末端に結合されたペプチド1および結合されていないペプチド1の両方と少し反応する能力、hIL-21を中和できるが、溶液からhIL-21-Fcを捕捉できないことに基づき、この抗体は、IL-21のN末端およびAヘリックスの領域中に存在し、かつ、Fc融合タンパク質に連結されているhIL-21の隣接したC末端の近くに空間を必要とすると予測される部分を含む、ヒトIL-21タンパク質構造体上のかなり不連続なエピトープに結合する。
Claims (16)
- SEQ ID NO：6のアミノ酸残基97〜122からなるヒトIL-21の抗原領域に結合する、抗IL-21モノクローナル抗体。
- ヒトIL-21タンパク質活性を中和し、ヒトIL-21-Fcタンパク質に結合し、ヒトIL-21ムテイン-Fcタンパク質に結合し、かつ、マウスIL-21-マウスFcタンパク質に結合する、請求項1記載の抗IL-21モノクローナル抗体。
- SEQ ID NO：6のアミノ酸残基145〜148からなるヒトIL-21の抗原領域に結合する、抗IL-21モノクローナル抗体。
- SEQ ID NO：6のアミノ酸残基154〜162に示される抗原領域にも結合する、請求項3記載の抗IL-21モノクローナル抗体。
- ヒトIL-21タンパク質活性を中和し、ヒトIL-21-Fcタンパク質に結合し、ヒトIL-21ムテイン-Fcタンパク質に結合せず、かつ、マウスIL-21-マウスFcタンパク質に結合する、請求項3記載の抗IL-21モノクローナル抗体。
- ヒトIL-21抗原の結合について、モノクローナル抗体272.21.1.3.4.2(ATCCアクセッション番号PTA-10395)と競合することができるビン(bin)。
- ヒトIL-21抗原の結合について、モノクローナル抗体268.5.1.11.42.1.4.3.9(ATCCアクセッション番号PTA-10394)と競合することができるビン。
- モノクローナル抗体272.21.1.3.4.2(ATCCアクセッション番号PTA-10395)が結合するエピトープに特異的に結合する、請求項6記載のモノクローナル抗体。
- モノクローナル抗体268.5.1.11.42.1.4.3.9(ATCCアクセッション番号PTA-10394)が結合するエピトープに特異的に結合する、請求項6記載のモノクローナル抗体。
- 検出可能なマーカーで標識された、請求項1、3、8、または9記載のモノクローナル抗体。
- 放射性同位元素、酵素、色素、およびビオチンからなる群より選択される検出可能なマーカーで標識された、請求項1、3、8、または9記載のモノクローナル抗体。
- 請求項1、3、8、または9記載のモノクローナル抗体を産生するハイブリドーマ細胞。
- 請求項12記載のモノクローナル抗体を産生するハイブリドーマ細胞。
- 以下の段階を含む、請求項1、3、8、または9記載のモノクローナル抗体を作製する方法：
(a)該モノクローナル抗体を産生することができるハイブリドーマを提供する段階;および
(b)該ハイブリドーマによる該モノクローナル抗体の産生を提供する条件下で、該ハイブリドーマを培養する段階。 - 自己免疫疾患を治療する方法であって、請求項1、3、8、または9記載の抗IL-21モノクローナル抗体の治療的有効量を患者に投与する段階を含む方法。
- 自己免疫疾患が、膵炎、I型糖尿病(IDDM)、グレーブス病、炎症性腸疾患(IBD)、クローン病、潰瘍性結腸炎、過敏性腸症候群、多発性硬化症、関節リウマチ、憩室症、全身性エリテマトーデス、乾癬、強直性脊椎炎、強皮症、全身性硬化症、乾癬性関節炎、変形性関節症、アトピー性皮膚炎、白斑、移植片対宿主病(GVHD)、皮膚T細胞リンパ腫(CTCL)、シェーグレン症候群、糸球体腎炎、IgA腎症、移植片対宿主病、移植拒絶、アトピー性皮膚炎、抗リン脂質症候群、および喘息、ならびに他の自己免疫疾患からなる群より選択される、請求項15記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74015405P | 2005-11-28 | 2005-11-28 | |
| US60/740,154 | 2005-11-28 | ||
| PCT/US2006/061277 WO2007111714A2 (en) | 2005-11-28 | 2006-11-28 | Il-21 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235520A Division JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009517405A JP2009517405A (ja) | 2009-04-30 |
| JP2009517405A5 true JP2009517405A5 (ja) | 2011-12-15 |
| JP5322653B2 JP5322653B2 (ja) | 2013-10-23 |
Family
ID=38541590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542537A Active JP5322653B2 (ja) | 2005-11-28 | 2006-11-28 | Ｉｌ−２１アンタゴニスト |
| JP2012235520A Active JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
| JP2015160266A Active JP6163520B2 (ja) | 2005-11-28 | 2015-08-17 | Ｉｌ−２１アンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235520A Active JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
| JP2015160266A Active JP6163520B2 (ja) | 2005-11-28 | 2015-08-17 | Ｉｌ−２１アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20070122413A1 (ja) |
| EP (3) | EP2567973B1 (ja) |
| JP (3) | JP5322653B2 (ja) |
| AU (1) | AU2006340750B2 (ja) |
| CA (1) | CA2632215A1 (ja) |
| DK (1) | DK1963369T3 (ja) |
| ES (2) | ES2491118T3 (ja) |
| PL (1) | PL1963369T3 (ja) |
| PT (1) | PT1963369E (ja) |
| WO (1) | WO2007111714A2 (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| PL1963369T3 (pl) | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
| KR101591316B1 (ko) * | 2007-12-07 | 2016-02-05 | 지모제넥틱스, 인코포레이티드 | 항-사람 ｉｌ-21 단클론성 항체 |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| WO2010041149A2 (en) * | 2008-10-08 | 2010-04-15 | Cambridge Enterprise | Methods and compositions for diagnosis and treatment |
| WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| CN103443124A (zh) * | 2011-01-17 | 2013-12-11 | 诺沃—诺迪斯克有限公司 | Il-21配体 |
| BR112013018046B1 (pt) | 2011-01-18 | 2023-01-31 | Bioniz, Llc | Conjugado peptídico, composição farmacêutica, métodos in vitro para bloquear sinalização por um ou mais membros de família citocina-yc e para inibir ligação de citocina-yc a subunidade-yc e uso de conjugado peptídico ou de composição farmacêutica |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| US20140170153A1 (en) * | 2011-05-31 | 2014-06-19 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
| US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
| HRP20230424T1 (hr) | 2012-06-28 | 2023-07-07 | University Of Central Florida Research Foundation Incorporated | Postupci i pripravci za prirodnoubilačke stanice |
| CN105579470B (zh) | 2013-06-27 | 2021-05-25 | 莫纳什大学 | Il-21结合蛋白和其用途 |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| WO2016073778A2 (en) | 2014-11-05 | 2016-05-12 | Nirmidas Biotech, Inc. | Metal composites for enhanced imaging |
| AU2015367224B2 (en) | 2014-12-19 | 2020-12-10 | Monash University | IL-21 antibodies |
| CA2971508A1 (en) * | 2014-12-19 | 2016-06-23 | Mabtech Ab | Composition, kit and method for inhibition of il-21 mediated activation of human cells |
| US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
| CN108350032A (zh) | 2015-10-09 | 2018-07-31 | 比奥尼斯有限责任公司 | 调节γC-细胞因子活性 |
| CA3018792C (en) | 2016-03-31 | 2023-03-28 | Eli Lilly And Company | Il-21 antibodies and uses thereof |
| KR20190139245A (ko) * | 2017-04-07 | 2019-12-17 | 바이오니즈, 엘엘씨 | 감마-c-사이토카인 활성의 안정한 조절자 |
| RU2667423C1 (ru) * | 2017-06-28 | 2018-09-19 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПраймБиоМед" | Мышиная гибридома ykl-39, клон 1b2 g4 - продуцент моноклонального антитела, обладающего специфичностью к цитоплазматическому антигену ykl-39 человека |
| MX2020001328A (es) | 2017-08-03 | 2020-03-20 | Amgen Inc | Muteinas de interleucina 21 y metodos de tratamiento. |
| CR20200330A (es) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anticuerpos anti-pd-1 y métodos de tratamiento |
| CA3117895A1 (en) | 2018-11-08 | 2020-05-14 | GammaDelta Therapeutics Limited | Methods for isolating and expanding cells |
| KR20220005082A (ko) | 2019-05-03 | 2022-01-12 | 바이오니즈, 엘엘씨 | 탈모 및 탈모 관련 문제증상 치료를 위한 감마-c-사이토카인 신호전달 효과 조절 |
| GB202006989D0 (en) | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| GB202105113D0 (en) | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| GB202204926D0 (en) | 2022-04-04 | 2022-05-18 | Gammadelta Therapeutics Ltd | Method for expanding gammadelta T cells |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
| US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| ATE140963T1 (de) | 1988-01-22 | 1996-08-15 | Zymogenetics Inc | Verfahren zur herstellung von sekretierten rezeptoranalogen |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69122313T2 (de) | 1990-06-21 | 1997-03-20 | Honeywell Inc | Auf variablem Horizont basierende adaptive Steuerung mit Mitteln zur Minimierung der Betriebskosten |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6057127A (en) * | 1998-01-29 | 2000-05-02 | Heska Corporation | Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US20010023070A1 (en) | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| AU4208799A (en) * | 1998-05-29 | 1999-12-13 | Human Genome Sciences, Inc. | Interleukins-21 and 22 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| RU2346951C2 (ru) | 1999-03-09 | 2009-02-20 | Займодженетикс, Инк. | Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты) |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| DK1749888T3 (da) | 2000-04-05 | 2010-05-10 | Zymogenetics Inc | Opløselige Zalph11a-cytokinreceptorer |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| DE10047189C1 (de) | 2000-09-23 | 2002-02-21 | Bosch Gmbh Robert | Verfahren zur Insassenklassifikation mit einer Sitzmatte im Fahrzeugsitz |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| DE60233888D1 (de) * | 2001-11-05 | 2009-11-12 | Zymogenetics Inc | Il-21-antagonisten |
| US20040028665A1 (en) | 2002-01-08 | 2004-02-12 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
| US20050063947A1 (en) | 2002-03-27 | 2005-03-24 | Patrick Hwu | Method for treating cancer in humans |
| AU2003230834A1 (en) | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| EP2377549A1 (en) | 2002-06-07 | 2011-10-19 | ZymoGenetics, Inc. | Use of IL-21 for treating viral infections |
| WO2004003156A2 (en) | 2002-07-01 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-21 as a regulator of immunoglobin production |
| WO2004007682A2 (en) * | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
| AU2003282752A1 (en) | 2002-10-08 | 2004-05-04 | Immunomedics, Inc. | Antibody therapy |
| US20070092485A1 (en) | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| JP3979276B2 (ja) * | 2002-11-29 | 2007-09-19 | 富士通株式会社 | 業務支援方法、業務支援装置、及びプログラム |
| DE60330044D1 (de) | 2002-12-13 | 2009-12-24 | Zymogenetics Inc | Il-21-produktion in prokaryontischen wirten |
| EP1575615A1 (en) | 2002-12-23 | 2005-09-21 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| KR20050119120A (ko) * | 2003-03-14 | 2005-12-20 | 와이어쓰 | 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도 |
| AU2004224277A1 (en) * | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| WO2005037306A1 (en) | 2003-10-17 | 2005-04-28 | Novo Nordisk A/S | Combination therapy |
| JP4471721B2 (ja) | 2004-04-20 | 2010-06-02 | 独立行政法人産業技術総合研究所 | 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ |
| CN1980698A (zh) * | 2004-05-19 | 2007-06-13 | 惠氏公司 | 免疫球蛋白产生和特应性疾病的调节 |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| US20060039902A1 (en) * | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| WO2006105538A2 (en) | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| DK200501310A (da) | 2005-09-21 | 2005-10-01 | Novo Nordisk As | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
| PL1963369T3 (pl) | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| KR101591316B1 (ko) | 2007-12-07 | 2016-02-05 | 지모제넥틱스, 인코포레이티드 | 항-사람 ｉｌ-21 단클론성 항체 |
| WO2009132821A1 (en) | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| CN103443124A (zh) | 2011-01-17 | 2013-12-11 | 诺沃—诺迪斯克有限公司 | Il-21配体 |
-
2006
- 2006-11-28 PL PL06850198T patent/PL1963369T3/pl unknown
- 2006-11-28 PT PT68501980T patent/PT1963369E/pt unknown
- 2006-11-28 JP JP2008542537A patent/JP5322653B2/ja active Active
- 2006-11-28 WO PCT/US2006/061277 patent/WO2007111714A2/en active Application Filing
- 2006-11-28 EP EP12192046.6A patent/EP2567973B1/en not_active Revoked
- 2006-11-28 ES ES12192046.6T patent/ES2491118T3/es active Active
- 2006-11-28 CA CA002632215A patent/CA2632215A1/en not_active Abandoned
- 2006-11-28 ES ES06850198T patent/ES2409835T3/es active Active
- 2006-11-28 EP EP06850198.0A patent/EP1963369B1/en not_active Revoked
- 2006-11-28 US US11/563,928 patent/US20070122413A1/en not_active Abandoned
- 2006-11-28 AU AU2006340750A patent/AU2006340750B2/en not_active Ceased
- 2006-11-28 DK DK06850198.0T patent/DK1963369T3/da active
- 2006-11-28 EP EP14163892.4A patent/EP2805971A1/en not_active Withdrawn
-
2008
- 2008-07-24 US US12/179,003 patent/US7923539B2/en active Active
-
2011
- 2011-03-01 US US13/037,585 patent/US8222374B2/en active Active
-
2012
- 2012-06-08 US US13/492,315 patent/US9388241B2/en active Active
- 2012-10-25 JP JP2012235520A patent/JP6027849B2/ja active Active
-
2015
- 2015-08-17 JP JP2015160266A patent/JP6163520B2/ja active Active
-
2016
- 2016-06-09 US US15/177,914 patent/US20170037123A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009517405A5 (ja) | ||
| WO2007111714B1 (en) | Il-21 antagonists | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| WO2018177393A1 (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| Shoham | Crystal Structure of an Anticholera Toxin Peptide Complex at 2· 3 Å | |
| CN109206514B (zh) | Tslp单克隆抗体及其制备方法和应用 | |
| JP2009517406A5 (ja) | ||
| US11345753B2 (en) | TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof | |
| Eggel et al. | DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage | |
| WO2019015282A1 (zh) | 靶向于白介素17a的抗体、其制备方法和应用 | |
| KR100855299B1 (ko) | 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법 | |
| CN114773473A (zh) | 抗cd39抗体及其制备方法和用途 | |
| CN110172097B (zh) | 一种抗结核分枝杆菌cfp-10蛋白的单克隆抗体及其应用 | |
| Hou et al. | Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling | |
| Zhang et al. | Chicken monoclonal IgY antibody: a novel antibody development strategy | |
| US11634481B2 (en) | B-cell epitope of Trichinella spiralis cysteine protease inhibitor, hybridoma cell line, monoclonal antibody and uses thereof | |
| CN114591423B (zh) | 新冠病毒n蛋白的特异性抗体及其制备方法与应用 | |
| Parkkinen et al. | Crystal structures of an enantioselective fab-fragment in free and complex forms | |
| JP2007075115A (ja) | 甲状腺機能を刺激する活性を持つ抗体 | |
| CN113817055B (zh) | 抗Actin蛋白单克隆抗体、细胞系及其应用 | |
| TW201925233A (zh) | 抗體、用於在樣品中偵測或捕捉多肽的組成物以及在樣品中偵測或捕捉多肽的方法 | |
| CN113583125B (zh) | 抗体以及包含其的结合剂、免疫吸附材料及其应用 | |
| CN110483642B (zh) | 烯酰-酰基载体蛋白还原酶的单克隆抗体及其应用 | |
| Kobayash et al. | Isolation of mimotopes to the anti-human VEGF antibody Bevacizumab by mRNA display using random peptide libraries and the vaccination of a rabbit |